Paxobrook

Paxobrook is a generic version of the antiviral drug Paxlovid, formulated to treat mild to moderate COVID-19 in individuals at high risk of progressing to severe disease. It combines two antiviral agents:

• Nirmatrelvir 150 mg – inhibits SARS-CoV-2 viral replication.
• Ritonavir 100 mg – boosts the effectiveness of nirmatrelvir by slowing its breakdown.

Paxobrook is most effective when started within 5 days of COVID-19 symptom onset.

Key Benefits

• Reduces risk of hospitalization and severe illness from COVID-19
• Oral tablets – no injection required
• Generic, cost-effective alternative to Paxlovid
• Suitable for adults and children (12+ years, ≥40 kg)

Product Details

• Brand: Paxobrook
• Generic Name: Nirmatrelvir + Ritonavir
• Form: Oral tablets
• Packaging: 30 tablets per box (5-day course)

Dosage & Administration

• Take 2 tablets of Nirmatrelvir 150 mg and 1 tablet of Ritonavir 100 mg together.
• Repeat this dose twice daily for 5 consecutive days.
• Do not crush or chew the tablets.
• Start treatment as early as possible, ideally within 5 days of symptom onset.

Precautions

• Not suitable for patients with severe kidney or liver impairment.
• Consult a doctor if pregnant, breastfeeding, or taking other medications.
• Ritonavir can interact with many other drugs – disclose your medication history to your doctor.

Possible Side Effects

• Metallic or altered taste
• Diarrhea
• Muscle aches
• High blood pressure
• Rare: Allergic reactions or liver enzyme changes

FAQs

Q1: What is Paxobrook used for?
Paxobrook is used to treat mild to moderate COVID-19 in patients at high risk of developing severe symptoms.

Q2: Is Paxobrook the same as Paxlovid?
Yes, it contains the same active ingredients – Nirmatrelvir and Ritonavir – and offers similar antiviral effects at a more affordable price.

Q3: Can I take Paxobrook without symptoms?
No. Paxobrook is not for prevention. It is only effective when taken shortly after COVID-19 symptoms appear.

Q4: Can children take Paxobrook?
It is approved for children 12 years and older who weigh at least 40 kg (88 lbs), under medical supervision.